Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Boehringer Ingelheim
Express Scripts
Mallinckrodt
Medtronic

Last Updated: November 14, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SECRETIN SYNTHETIC HUMAN

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Secretin Synthetic Human

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00036231 Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction Terminated Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine the effect of multiple doses of secretin on autism.
NCT00036244 Synthetic Human Secretin in Children With Autism Completed Repligen Corporation Phase 3 2002-04-01 The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
NCT00065962 Secretin for the Treatment of Autism Completed National Institute on Deafness and Other Communication Disorders (NIDCD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00065962 Secretin for the Treatment of Autism Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1999-06-01 Many drugs used to treat autism target specific symptoms, such as hyperactivity and aggressiveness. Few drugs target the core autistic symptoms of impaired social interaction and communication. This study will evaluate two forms of the drug secretin for the treatment of core autistic symptoms.
NCT00216294 Safety Study of the Drug RG1068 in Patients With Obsessive Compulsive Disorder Completed Repligen Corporation Phase 2 2005-02-01 The purpose of this study is to determine the safety and tolerability of RG1068 (Synthetic Human Secretin) when administered three times weekly to outpatients with obsessive compulsive disorder (OCD), to determine the impact of multiple subcutaneous injections of RG1068 on the symptoms of OCD, as measured by changes in clinical scales, and to evaluate the effect of RG1068 on ODC patients' anxiety, quality of life, and depression.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Secretin Synthetic Human

Condition Name

Condition Name for Secretin Synthetic Human
Intervention Trials
Autism 3
Chronic Pancreatitis 2
Pancreatic Disease 1
Obsessive Compulsive Disorder (OCD) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Secretin Synthetic Human
Intervention Trials
Pancreatitis 4
Autistic Disorder 3
Pancreatitis, Chronic 2
Obsessive-Compulsive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Secretin Synthetic Human

Trials by Country

Trials by Country for Secretin Synthetic Human
Location Trials
United States 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Secretin Synthetic Human
Location Trials
Massachusetts 4
Washington 2
Indiana 2
Colorado 2
New Hampshire 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Secretin Synthetic Human

Clinical Trial Phase

Clinical Trial Phase for Secretin Synthetic Human
Clinical Trial Phase Trials
Phase 3 5
Phase 2 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Secretin Synthetic Human
Clinical Trial Phase Trials
Completed 5
Terminated 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Secretin Synthetic Human

Sponsor Name

Sponsor Name for Secretin Synthetic Human
Sponsor Trials
Repligen Corporation 4
Massachusetts General Hospital 3
ChiRhoClin, Inc. 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Secretin Synthetic Human
Sponsor Trials
Other 6
Industry 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
AstraZeneca
McKesson
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.